The Pregnancy in Polycystic Ovary Syndrome II (PPCOS II) trial: Rationale and design of a double-blind randomized trial of clomiphene citrate and letrozole for the treatment of infertility in women with polycystic ovary syndrome

Contemporary Clinical Trials

Volumn 33, Issue 3, 2012, Pages 470-481

  Legro, Richard S ^a   Kunselman, Allen R ^a   Brzyski, Robert G ^b   Casson, Peter R ^c   Diamond, Michael P ^d   Schlaff, William D ^e   Christman, Gregory M ^f   Coutifaris, Christos ^g   Taylor, Hugh S ^h   Eisenberg, Esther ⁱ   Santoro, Nanette ^e   Zhang, Heping ^h  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c UNIVERSITY OF VERMONT   (United States)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

Clomiphene citrate; Hyperandrogenism; Infertility; Letrozole; Ovulation induction; Polycystic Ovary Syndrome

Indexed keywords

CLOMIFENE CITRATE; LETROZOLE;

ADULT; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEMALE INFERTILITY; HUMAN; LIVE BIRTH; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVARY POLYCYSTIC DISEASE; OVULATION; POPULATION RESEARCH; PREGNANCY; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CHI-SQUARE DISTRIBUTION; CLOMIPHENE; DOUBLE-BLIND METHOD; FEMALE; FERTILITY AGENTS, FEMALE; HEALTH STATUS INDICATORS; HIRSUTISM; HUMANS; HYPERANDROGENISM; INFERTILITY, FEMALE; MIDDLE AGED; NITRILES; OVULATION INDUCTION; POLYCYSTIC OVARY SYNDROME; PREGNANCY; QUALITY OF LIFE; RESEARCH DESIGN; TRIAZOLES; WOMEN'S HEALTH; YOUNG ADULT;

EID: 84862832321     PISSN: 15517144     EISSN: 15592030     Source Type: Journal    
DOI: 10.1016/j.cct.2011.12.005     Document Type: Article

References (48)

1. Hull M.G. Epidemiology of infertility and polycystic ovarian disease: endocrinological and demographic studies. Gynecol Endocrinol 1987, 1:235-245.
2. Homburg R., Armar N.A., Eshel A., Adams J., Jacobs H.S. Influence of serum luteinising hormone concentrations on ovulation, conception, and early pregnancy loss in polycystic ovary syndrome. BMJ 1988, 297:1024-1026.
3. Bjercke S., Dale P.O., Tanbo T., Storeng R., Ertzeid G., Abyholm T. Impact of insulin resistance on pregnancy complications and outcome in women with polycystic ovary syndrome. Gynecol Obstet Invest 2002, 54(2):94-98.
4. Ehrmann D.A. Polycystic ovary syndrome. N Engl J Med Mar 24 2005, 352(12):1223-1236.
5. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril Jan 2004, 81(1):19-25.
6. Legro R.S., Myers E. Surrogate end-points or primary outcomes in clinical trials in women with polycystic ovary syndrome?. Hum Reprod Aug 2004, 19(8):1697-1704.
7. Johnson N.P. No more surrogate end-points in randomised trials: the PCOSMIC trial protocol for women with polycystic ovary syndrome using metformin for infertility with clomiphene. Aust N Z J Obstet Gynaecol Apr 2006, 46(2):141-145.
8. Legro R.S., Barnhart H.X., Schlaff W.D., Carr B.R., Diamond M.P., Carson S.A., et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med Feb 8 2007, 356(6):551-566.
9. Tulandi T., Martin J., Al-Fadhli R., Kabli N., Forman R., Hitkari J., et al. Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate. Fertil Steril Jun 2006, 85(6):1761-1765.
10. Holzer H., Casper R., Tulandi T. A new era in ovulation induction. Fertil Steril Feb 2006, 85(2):277-284.
11. Tredway D.R., Buraglio M., Hemsey G., Denton G. A phase I study of the pharmacokinetics, pharmacodynamics, and safety of single- and multiple-dose anastrozole in healthy, premenopausal female volunteers. Fertil Steril Dec 2004, 82(6):1587-1593.
12. Atay V., Cam C., Muhcu M., Cam M., Karateke A. Comparison of letrozole and clomiphene citrate in women with polycystic ovaries undergoing ovarian stimulation. J Int Med Res Jan-Feb 2006, 34(1):73-76.
13. Bayar U., Tanriverdi H.A., Barut A., Ayoglu F., Ozcan O., Kaya E. Letrozole vs. clomiphene citrate in patients with ovulatory infertility. Fertil Steril Apr 2006, 85(4):1045-1048.
14. Mitwally M.F., Casper R.F. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril Feb 2001, 75(2):305-309.
15. Al-Omari W.R., Sulaiman W.R., Al-Hadithi N. Comparison of two aromatase inhibitors in women with clomiphene-resistant polycystic ovary syndrome. Int J Gynaecol Obstet Jun 2004, 85(3):289-291.
16. Elnashar A., Fouad H., Eldosoky M., Saeid N. Letrozole induction of ovulation in women with clomiphene citrate-resistant polycystic ovary syndrome may not depend on the period of infertility, the body mass index, or the luteinizing hormone/follicle-stimulating hormone ratio. Fertil Steril Feb 2006, 85(2):511-513.
17. Hatch R., Rosenfield R.L., Kim M.H., Tredway D. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol Aug 1 1981, 140(7):815-830.
18. Miller K.K., Rosner W., Lee H., Hier J., Sesmilo G., Schoenfeld D., et al. Measurement of free testosterone in normal women and women with androgen deficiency: comparison of methods. J Clin Endocrinol Metab Feb 2004, 89(2):525-533.
19. Balen A.H., Laven J.S., Tan S.L., Dewailly D. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update Nov-Dec 2003, 9(6):505-514.
20. Pariser D.M., Thiboutot D.M., Clark S.D., Jones T.M., Liu Y., Graeber M. The efficacy and safety of adapalene gel 0.3% in the treatment of acne vulgaris: a randomized, multicenter, investigator-blinded, controlled comparison study versus adapalene gel 0.1% and vehicle. Cutis Aug 2005, 76(2):145-151.
21. Thiboutot D.M., Shalita A.R., Yamauchi P.S., Dawson C., Arsonnaud S., Kang S. Combination therapy with adapalene gel 0.1% and doxycycline for severe acne vulgaris: a multicenter, investigator-blind, randomized, controlled study. Skinmed May-Jun 2005, 4(3):138-146.
22. Leyden J.J., Shalita A., Thiboutot D., Washenik K., Webster G. Topical retinoids in inflammatory acne: a retrospective, investigator-blinded, vehicle-controlled, photographic assessment. Clin Ther Feb 2005, 27(2):216-224.
23. Leyden J., Thiboutot D.M., Shalita A.R., Webster G., Washenik K., Strober B.E., et al. Comparison of tazarotene and minocycline maintenance therapies in acne vulgaris: a multicenter, double-blind, randomized, parallel-group study. Arch Dermatol May 2006, 142(5):605-612.
24. Thiboutot D.M., Shalita A.R., Yamauchi P.S., Dawson C., Kerrouche N., Arsonnaud S., et al. Adapalene gel, 0.1%, as maintenance therapy for acne vulgaris: a randomized, controlled, investigator-blind follow-up of a recent combination study. Arch Dermatol May 2006, 142(5):597-602.
25. Thiboutot D., Pariser D.M., Egan N., Flores J., Herndon J.H., Kanof N.B., et al. Adapalene gel 0.3% for the treatment of acne vulgaris: a multicenter, randomized, double-blind, controlled, phase III trial. J Am Acad Dermatol Feb 2006, 54(2):242-250.
26. Ware J.E., Kosinski M., Gandek B. SF-36 health survey manual and interpretation guide 1993, Boston: New England Medical Center: The Health Institute.
27. Rosen R., Brown C., Heiman J., Leiblum S., Meston C., Shabsigh R., et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther Apr-Jun 2000, 26(2):191-208.
28. Rosen R.C., Riley A., Wagner G., Osterloh I.H., Kirkpatrick J., Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology Jun 1997, 49(6):822-830.
29. Boivin J., Takefman J., Braverman A. The fertility quality of life (FertiQoL) tool: development and general psychometric properties. Hum Reprod Aug 2011, 26(8):2084-2091.
30. Boivin J., Takefman J., Braverman A. The Fertility Quality of Life (FertiQoL) tool: development and general psychometric properties. Fertil Steril Aug 2011, 96(2):409-415.
31. Cronin L., Guyatt G., Griffith L., Wong E., Azziz R., Futterweit W., et al. Development of a health-related quality-of-life questionnaire (PCOSQ) for women with polycystic ovary syndrome (PCOS). J Clin Endocrinol Metab Jun 1998, 83(6):1976-1987.
32. Guyatt G., Weaver B., Cronin L., Dooley J.A., Azziz R. Health-related quality of life in women with polycystic ovary syndrome, a self-administered questionnaire, was validated. J Clin Epidemiol Dec 2004, 57(12):1279-1287.
33. Vgontzas A.N., Legro R.S., Bixler E.O., Grayev A., Kales A., Chrousos G.P. Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness: role of insulin resistance. J Clin Endocrinol Metab Feb 2001, 86(2):517-520.
34. Tasali E., Van Cauter E., Ehrmann D.A. Relationships between sleep disordered breathing and glucose metabolism in polycystic ovary syndrome. J Clin Endocrinol Metab Jan 2006, 91(1):36-42.
35. Kump K., Whalen C., Tishler P.V., Browner I., Ferrette V., Strohl K.P., et al. Assessment of the validity and utility of a sleep-symptom questionnaire. Am J Respir Crit Care Med Sep 1994, 150(3):735-741.
36. Guermandi E., Vegetti W., Bianchi M.M., Uglietti A., Ragni G., Crosignani P. Reliability of ovulation tests in infertile women. Obstet Gynecol Jan 2001, 97(1):92-96.
37. Laird N.M., Ware J.H. Random-effects models for longitudinal data. Biometrics Dec 1982, 38(4):963-974.
38. Pagidas K., Carson S.A., McGovern P.G., Barnhart H.X., Myers E.R., Legro R.S., et al. Intercourse compliance, ovulation, and treatment success in the National Institute of Child Health and Human Development-Reproductive Medicine Network's Pregnancy in Polycystic Ovary Syndrome (PPCOS) Trial. Fertil Steril Sep 2010, 94(4):1444-1446.
39. Melcangi R.C., Panzica G., Garcia-Segura L.M. Neuroactive steroids: focus on human brain. Neuroscience 2011, 191:1-5.
40. Jackson R.A., Gibson K.A., Wu Y.W., Croughan M.S. Perinatal outcomes in singletons following in vitro fertilization: a meta-analysis. Obstet Gynecol Mar 2004, 103(3):551-563.
41. Olson C.K., Keppler-Noreuil K.M., Romitti P.A., Budelier W.T., Ryan G., Sparks A.E., et al. In vitro fertilization is associated with an increase in major birth defects. Fertil Steril Nov 2005, 84(5):1308-1315.
42. Niemitz E.L., Feinberg A.P. Epigenetics and assisted reproductive technology: a call for investigation. Am J Hum Genet Apr 2004, 74(4):599-609.
43. Tredway D., Schertz J.C., Bock D., Hemsey G., Diamond M.P. Anastrozole single-dose protocol in women with oligo- or anovulatory infertility: results of a randomized phase II dose-response study. Fertil Steril Apr 2011, 95(5):1725-1729.
44. Tredway D., Schertz J.C., Bock D., Hemsey G., Diamond M.P. Anastrozole vs. clomiphene citrate in infertile women with ovulatory dysfunction: a phase II, randomized, dose-finding study. Fertil Steril Apr 2011, 95(5):1720-1724.
45. Badawy A., Mosbah A., Shady M. Anastrozole or letrozole for ovulation induction in clomiphene-resistant women with polycystic ovarian syndrome: a prospective randomized trial. Fertil Steril May 2008, 89(5):1209-1212.
46. Casson P.R., Krawetz S.A., Diamond M.P., Zhang H., Legro R.S., Schlaff W.D., et al. for the Reproductive Medicine Network. Establishing a biologic specimens repository for reproductive clinical trials: technical aspects. Syst Biol Reprod Med 2011, 57(5):222-227.
47. Begum M.R., Ferdous J., Begum A., Quadir E. Comparison of efficacy of aromatase inhibitor and clomiphene citrate in induction of ovulation in polycystic ovarian syndrome. Fertil Steril Sep 2009, 92(3):853-857.
48. Mitwally M.F., Casper R.F. Aromatase inhibition: a novel method of ovulation induction in women with polycystic ovary syndrome. Reprod Technol 2000, 10:244-247.